The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Thomas Zilli, Piet Dirix, Reino Heikkilä, Nick Liefhooghe, Shankar Siva, Alfonso Gomez-Iturriaga, Wouter Everaerts, François Otte, Mohamed Shelan, Carole Mercier, Vérane Achard, Kristian Thon, Karin Stellamans, Daniel Moon, Antonio Conde-Moreno, Alexandros Papachristofilou, Marta Scorsetti, Matthias Gückenberger, Filip Ameye, Almudena Zapatero, Lien Van De Voorde, Fernando López Campos, Felipe Couñago, Maud Jaccard, An Spiessens, Isabelle Semac, Frederik Vanhoutte, Els Goetghebeur, Dries Reynders, Piet Ost, Thomas Zilli, Piet Dirix, Reino Heikkilä, Nick Liefhooghe, Shankar Siva, Alfonso Gomez-Iturriaga, Wouter Everaerts, François Otte, Mohamed Shelan, Carole Mercier, Vérane Achard, Kristian Thon, Karin Stellamans, Daniel Moon, Antonio Conde-Moreno, Alexandros Papachristofilou, Marta Scorsetti, Matthias Gückenberger, Filip Ameye, Almudena Zapatero, Lien Van De Voorde, Fernando López Campos, Felipe Couñago, Maud Jaccard, An Spiessens, Isabelle Semac, Frederik Vanhoutte, Els Goetghebeur, Dries Reynders, Piet Ost
Abstract
Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021.
Trial registration: ClinicalTrials.gov NCT03569241.
Copyright © 2020 European Association of Urology. All rights reserved.
Source: PubMed